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Infant Nutritional Status and Markers of Environmental Enteric
Dysfunction are Associated with Midchildhood Anthropometry and Blood
Pressure in Tanzania
Lindsey M. Locks, ScD, MPH1, Ramadhani S. Mwiru, ScD, MSc2, Expeditho Mtisi, PhD, MSc, MS3,
Karim P. Manji, MBBS, MMED, MPH4, Christine M. McDonald, MS, ScD5, Enju Liu, PhD6, Roland Kupka, ScD1,7,
Rodrick Kisenge, MD, MMed, PhD4, Said Aboud, MD, PhD8, Kerri Gosselin, MD5, Matthew Gillman, MD, SM1,9,
Andrew T. Gewirtz, PhD10, Wafaie W. Fawzi, DrPH, MBBS, MPH, MS1,11,12, and Christopher P. Duggan, MD, MPH1,4,12
Objective To assess whether growth and biomarkers of environmental enteric dysfunction in infancy are related
to health outcomes in midchildhood in Tanzania.
Study design Children who participated in 2 randomized trials of micronutrient supplements in infancy were fol-
lowed up in midchildhood (4.6-9.8 years of age). Anthropometry was measured at age 6 and 52 weeks in both
trials, and blood samples were available from children at 6 weeks and 6 months from 1 trial. Linear regression
was used for height-for-age z-score, body mass index-for-age z-score, and weight for age z-score, and blood pres-
sure analyses; log-binomial models were used to estimate risk of overweight, obesity, and stunting in midchildhood.
Results One hundred thirteen children were followed-up. Length-for-age z-score at 6 weeks and delta length-
for-age z-score from 6 to 52 weeks were associated independently and positively with height-for-age z-score and
inversely associated with stunting in midchildhood. Delta weight-for-length and weight-for-age z-score were also
positively associated with midchildhood height-for-age z-score. The 6-week and delta weight-for-length z-scores
were associated independently and positively with midchildhood body mass index-for-age z-score and over-
weight, as was the 6-week and delta weight-for-age z-score. Delta length-for-age z-score was also associated with
an increased risk of overweight in midchildhood. Body mass index-for-age z-score in midchildhood was associ-
ated positively with systolic blood pressure. Serum anti-flagellin IgA concentration at 6 weeks was also associated
with increased blood pressure in midchildhood.
Conclusions Anthropometry at 6 weeks and growth in infancy independently predict size in midchildhood, while
anti-flagellin IgA, a biomarker of environmental enteric dysfunction, in early infancy is associated with increased
blood pressure in midchildhood. Interventions in early life should focus on optimizing linear growth while minimiz-
ing excess weight gain and environmental enteric dysfunction. (J Pediatr 2017;■■:■■-■■).
Trial registration ClinicalTrials.gov: NCT00197730 and NCT00421668.
T he prevalence of childhood overweight and obesity is increasing in almostevery region of the world.1 At the same time, several low- and middle-income countries continue to confront high rates of undernutrition and
impaired child growth, and are thus simultaneously facing a dual burden of mal-
nutrition among children. In low-resource settings in particular, where 156 million
children under 5 years of age experience chronic undernutrition,2 the wide-
spread prevalence of undernutrition and impaired growth in early life may have
profound impacts on long-term health outcomes. Children who suffer from un-
dernutrition in early life are more likely to have reduced adult stature, impaired
cognitive development, lower earning potential, and if they are women, also a higher
risk of birth complications.3 Furthermore, the developmental origins of health
and disease paradigm proposes that perturbations in the homeostasis of a
BMIZ Body mass index-for-age z-score
EED Environmental enteric dysfunction
HAZ Height-for-age z-score
LAZ Length-for-age z-score
LPS Lipopolysaccharide
WAZ Weight-for-age z-score
WHO World Health Organization
WLZ Weight-for-length z-score
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developing fetus or infant result in long-term changes affect-
ing that individual’s risk of future diseases.4 Several studies have
documented an increased risk of cardiometabolic risk factors,
such as high blood pressure, dyslipidemia, and insulin resis-
tance, among individuals who were born at a low birth weight5-8
and among those with a low body mass index-for-age z-score
(BMIZ) in early childhood.6,9,10 The relative importance of peri-
natal versus infant growth in long-term health outcomes,
however, is unknown. Furthermore, much of the evidence on
the relationship between early life growth and adult health out-
comes comes from wealthy nations,5,9,11 despite the growing
evidence that the relative influence on growth in early life on
later-life health outcomes may be population specific.12 Spe-
cifically, there is limited research from sub-Saharan Africa, where
the risk factors for poor growth as well as chronic disease out-
comes are likely quite different from those in developed nations.
Recent data suggest that environmental enteric dysfunc-
tion (EED), a subclinical condition of the small intestine char-
acterized by villous atrophy, crypt hyperplasia, increased
intestinal permeability, inflammatory cell infiltrate, and mal-
absorption, is associated with growth failure and stunting.13-15
Some have also hypothesized that EED may increase the risk
for cardiometabolic diseases in later life, including insulin re-
sistance and hypertension.16 Although the gold standard for
assessing EED is small bowel biopsy, the invasive and expen-
sive nature of these procedures has led researchers to pursue
biomarkers that are more suitable for widespread use in
community-based settings. Our group has assessed previ-
ously the use of anti-flagellin and anti-lipopolysaccharide (LPS)
IgA and IgG as biomarkers of EED. We found that anti-LPS
and anti-flagellin IgA and IgG concentrations increased over
the first year of life in Tanzanian infants, that the concentra-
tions in Tanzanian infants were significantly higher than in
healthy controls in Boston, and that elevated anti-LPS and anti-
flagellin IgA and IgG concentrations were associated with an
increased risk of underweight in infancy.17 In our current study,
we assess whether these biomarkers continue to be associ-
ated with growth and health outcomes in midchildhood.
Given the limited research on how nutritional status and EED
in early infancy relate to long-term growth and cardiometabolic
risk factors in children in low-resource settings, we collected
data from a cohort of children in Dar es Salaam, Tanzania, to
assess the relative importance of infant growth and nutri-
tional status at age 6 weeks of age and change from 6 to 52
weeks of age, as well as biomarkers of EED in infancy, on health
and growth outcomes in midchildhood.
Methods
The study sample included children born in Dar es Salaam,
Tanzania, who participated in 1 of 2 randomized controlled
trials of multiple micronutrient supplementation to infants.
The first trial (ClinicalTrials.gov: NCT00197730) random-
ized 2387 infants born to HIV-infected mothers to either daily
administration of multiple micronutrients (vitamins B complex,
C, and E) or placebo at 6 weeks of age.18 Randomization of
infants occurred between August 2004 and November 2007;
follow-up ended in May 2008. The micronutrient supple-
ments did not show an effect on mortality, morbidity, or child
growth.18,19 The second trial (ClinicalTrials.gov: NCT00421668)
was implemented with a 2 × 2 factorial design assessing
the effect of zinc, zinc plus multivitamins (the same combi-
nation of vitamins B complex, C, and E as described),
multivitamins alone, or placebo among 2400 infants born to
HIV-negative women.20 The second trial found that zinc supple-
mentation reduced the risk of acute respiratory and diar-
rheal infections,20 but that neither supplement alone nor in
combination had an effect on rates of stunting, wasting, or
underweight.21 The 2 studies were designed to allow for pooled
analyses—they were conducted in overlapping clinics with
similar staff, they used identical inclusion/exclusion criteria
(other than maternal HIV status), and they collected the same
sociodemographic and clinical data on all mothers and chil-
dren. In both trials, infants were randomized at 6 weeks of age,
and mothers were asked to bring the children to the clinic for
follow-up visits every 4 weeks after randomization. At each
monthly follow-up visit, a trained study nurse measured child
anthropometry using standard techniques.22 Weight was mea-
sured on a digital infant balance scale with 10-g precision
(Tanita, Arlington Heights, Illinois) and length with 1-mm pre-
cision using a rigid length board with an adjustable foot piece.
For the current study, we identified children who partici-
pated in the 2 original trials who met the following criteria:
children with complete physical descriptions of their home ad-
dresses on file, who had anthropometric data at 6 weeks, who
had participated in their original trial through 15 months of
age, and who were available for contact during the follow-up
study recruitment period of June to August 2014. From the
2387 children in the first trial, a list of all children who ful-
filled these criteria was generated and simple random sam-
pling was used to select children for follow-up. From the 2400
children in the second trial, we selected from 269 children who
had participated in an enteric disease substudy because these
children had provided blood specimens at both 6 weeks and
6 months of age.17 Further inclusion criteria in the substudy
was that children had length-for-age z-score (LAZ) > −2 at 6
weeks.
Laboratory Assessments
Microtiter plates were coated with purified Escherichia coli
flagellin (100 ng/well) or purified Escherichia coli LPS (2 mg/
well). Serum samples from study participants were diluted 1:200
and applied to wells coated with flagellin or LPS. After incu-
bation and washing, the wells were incubated with anti-
human IgA (KPL, Milford, Massachusetts) or IgG (GE
Healthcare, Little Chalfont, United Kingdom) coupled to a
horseradish peroxidase. The quantification of total immuno-
globulins was performed with the use of the colorimetric per-
oxidase substrate tetramethylbenzidine, and absorbance (optical
density) was read at 450 nm with the use of an enzyme-
linked immunosorbent assay plate reader. Data are reported
as optical density-corrected data by subtracting background
concentrations, which were determined from the readings in
samples that lacked serum.
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Follow-Up Assessments
For all children who participated in the follow-up study, trained
study nurses measured their weight, height, and blood pres-
sure when the children were between 4 and 9 years of age. Dia-
stolic, systolic, and mean arterial blood pressure in mm Hg were
measured with a DINAMAP DPC120X-EN (GE Medical
Systems Information Technologies Inc, Milwaukee, Wiscon-
sin). Blood pressure measurements were assessed 5 times by
a single observer and then averaged. Body weight was mea-
sured with an electronic digital scale accurate to 0.1 kg (Tanita),
and standing height was measured with a stadiometer to the
nearest 0.1 cm.
Ethical approval for both parent trials was granted by the
Harvard T.H. Chan School of Public Health Human Subjects
Committee, the Muhimbili University of Health and Allied Sci-
ences Committee of Research and Publications, the Tanza-
nian Institute for Medical Research, and the Tanzanian Food
and Drug Authority; the follow-up study was approved by the
Harvard T.H. Chan School of Public Health Human Subjects
Committee and the Muhimbili University of Health and Allied
Sciences Committee of Research and Publications. All mothers
provided written informed consent to enroll themselves and
their children in the original and follow-up studies.
Statistical Analyses
Details on data collection and management from the 2 trials
have been published previously.18-21 In brief, data were double
entered by using Microsoft Access software and converted to
SAS datasets (version 9.4; SAS Institute, Cary, North Caro-
lina) for analysis. For growth analyses, we calculated age- and
sex-specific z-scores for 3 anthropometric indices during
infancy: weight-for-length z-score (WLZ), LAZ, and weight-
for-age z-score (WAZ) using the 2006 World Health Organi-
zation (WHO) growth standards.23 In accordance with WHO
recommendations, we set all extreme LAZ (<−6 or >6), WLZ
(<−5 or >5), and WAZ (<−6 or >5) values to missing.24 For
follow-up anthropometric data, we calculated age- and sex-
standardized height-for-age z-score (HAZ), WAZ, and BMIZ
using the 2006 WHO growth standards for children younger
than 5 years of age and the WHO 2007 Growth Reference for
children aged 5 years and older.25 In accordance with WHO
guidelines, stunting was defined as HAZ <−2, and over-
weight as BMIZ >1, and obese as BMIZ >2.
Descriptive statistics, including means with standard de-
viations and frequencies with percentages, were used to sum-
marize sociodemographic information on maternal, child, and
household characteristics as well as the growth characteris-
tics of children who participated in the follow-up study. Our
outcomes of interest were HAZ, BMIZ, and WAZ; systolic and
diastolic blood pressures; and overweight, obesity, and stunt-
ing in midchildhood. Our exposures of interest were base-
line anthropometric indicators (6-week LAZ, WAZ, and WLZ)
and change in each anthropometric indicator from 6 to 52
weeks of age, as well as EED biomarkers (anti-flagellin and anti-
LPS IgG and IgA) at 6 weeks and 6 months of age. For each
continuous outcome of interest, we first conducted univari-
ate linear regression models with each anthropometric and EED
biomarker as predictors of interest. Confounders for multi-
variate models were selected based on a review of the litera-
ture and included which trial the child originally participated
in, the trial treatment arm, and the child’s sex for all models;
maternal height and maternal education for all models for an-
thropometric outcomes; and child’s gestational age at birth as
well as age at midchildhood follow-up for all blood pressure
models. Multivariate models assessing the effect of anthro-
pometry in infancy included each anthropometric indicator
at 6 weeks of age as well as the change in the same indicator
from 6 to 52 weeks of age to assess relative importance of the
2 time periods for each indicator. The assumption of linear-
ity was assessed using plots of residuals versus predicted values,
and normality based on normal quantile plots.
For our primary outcomes (anthropometry and blood pres-
sure in midchildhood), data from 113 subjects and 8 covariates
in the multivariate linear regression models, provided 80%
power to detect a minimal increase of 7% in the R2 value for
a predictor of interest at significance level of 0.05. In models
where biomarkers of EED were predictors of interest, the
number of subjects was reduced to 66 in our analysis, which
provided 80% power to detect a minimal increase of 12% in
R2 value at a significance level of 0.05. We also conducted uni-
variate and multivariate log-binomial regression models to
assess the relationship between each of our predictors of in-
terest and overweight, obesity, and stunting in midchildhood.
Given the limited power to assess these outcomes, multivari-
ate models for binary anthropometric outcomes only adjust
for which trial the child participated in, the child’s sex, and
the corresponding anthropometric indicator at baseline or
change from 6 to 52 weeks of age. Multivariate models for stunt-
ing in midchildhood also adjust for maternal height. All analy-
ses were conducted in SAS version 9.4 (SAS Institute).
Results
Research staff attempted to contact 327 children and success-
fully reconsented and re-enrolled 113 children, 47 from the first
trial (children born to HIV-infected mothers, none of whom
had tested positive for HIV) and 66 from the second trial (chil-
dren born to HIV-uninfected mothers). All 66 children from
the second trial had blood samples drawn at 6 weeks and 6
months of age. There were no differences in sociodemo-
graphic characteristics or early infant growth indicators when
comparing children who participated in the follow-up study
and the original trials with the exceptional of gestational age
in weeks, which was slightly longer in children in the follow-
up study compared with the parent trials (40.0 ± 2.3 vs.
39.4 ± 2.7). Mean LAZ, WLZ, and WAZ were already below 0
at 6 weeks of age, and the means continued to decline through
age 12 months (Table I). The age range for children at follow-
up was 4.6-9.8 years (6.8 ± 1.6 years). Children born to
HIV-infected mothers (participants in trial 1) were older at
follow-up than children born to HIV-uninfected mothers (par-
ticipants in trial 2). The prevalence of stunting, thinness, over-
weight, and obesity at follow-up were 4.4%, 5.3%, 8.0%, and
3.5%, respectively.
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In multivariate models predicting HAZ in midchildhood,
LAZ at age 6 weeks and change in LAZ, WLZ, and WAZ from
6 to 52 weeks of age were all correlated positively with HAZ
in midchildhood (Table II). Of note, in the model contain-
ing 6-week LAZ and change in LAZ from 6 to 52 weeks of age,
both variables were significant, independent predictors of
midchildhood HAZ (Beta 0.47 [95% CI 0.25-0.68; P < .001]
and 0.40 [95% CI 0.20-0.61; P < .001], respectively). None of
the EED biomarkers at 6 weeks or 6 months of age were as-
sociated significantly with HAZ or any of the anthropomet-
ric indicators in midchildhood. We also did not find that
treatment in either trial was associated with HAZ in
midchildhood or any of the anthropometric indicators.
In the multivariate model adjusting for sociodemographic
characteristics, WLZ at 6 weeks of age and change in WLZ from
6 to 52 weeks of age were associated independently with BMIZ
in midchildhood (Beta 0.64 [95% CI 0.42-0.87; P < .001] and
0.38 [95% CI 0.21-0.54; P < .001], respectively). Similarly, WAZ
at 6 weeks of age and change from 6 to 52 weeks of age were
also associated independently with an increase in BMIZ in
midchildhood, although the effect estimates were slightly
smaller. In multivariate models, 6-week LAZ was not associ-
ated significantly with BMIZ in midchildhood, whereas the
change in LAZ from 6 to 52 weeks of age was marginally, sig-
nificantly correlated with BMIZ at follow-up. In multivariate
models for WAZ in midchildhood, baseline LAZ and change
in LAZ from 6 to 52 weeks of age were correlated indepen-
dently positively with WAZ, as were baseline WAZ and change
in WAZ, and baseline WLZ and change in WLZ.
None of the anthropometric indicators at baseline, nor
changes from 6 to 52 weeks of age, were significant predic-
tors of systolic or diastolic blood pressures at follow-up in the
univariate or multivariate models (Table III). Each addi-
tional unit in BMIZ in midchildhood, however, was associ-
ated with an increase in systolic blood pressure of 2.21 mm
Hg (95% CI 0.40-4.02; P = .02). We also found that flagellin
IgA at 6 weeks was a significant predictor of systolic blood pres-
sure in midchildhood in models adjusted for sociodemo-
graphic characteristics (Figure). Flagellin IgA at 6 weeks of age
was also associated linearly with diastolic blood pressure in
midchildhood in multivariate models. To enhance interpret-
ability, we compared quartiles of flagellin IgA and found that
children in the highest quartile of flagellin IgA at 6 weeks of
age had a mean systolic blood pressure that was 10.3 mm Hg
higher (95% CI 2.49-18.11) than infants in the lowest quartile
of flagellin IgA at 6 weeks of age in the multivariate models.
In additional analyses, we included baseline values and changes
in pediatric anthropometry in multivariate models assessing
flagellin IgA at 6 weeks of age as a predictor of systolic and
diastolic blood pressure in midchildhood; flagellin IgA at 6
weeks of age remained a significant predictor of both blood
pressure measures, even after adjusting for infant anthropom-
etry. None of the EED biomarkers at 6 months of age were sig-
nificant predictors of either blood pressure variable in
multivariate models.
In multivariate models for binary outcomes in midchildhood,
we found that both baseline WLZ and change in WLZ from
6 to 52 weeks of age, as well as baseline WAZ and change in
WAZ, were associated independently and positively with the
risk of being overweight in midchildhood (Table IV; avail-
able at www.jpeds.com). Of note, each unit increase in base-
line WLZ was associated with a 2.5-fold increase in risk of being
overweight in midchildhood (aRR 2.47; 95% CI 1.04-5.90) after
adjusting for change in WLZ from 6 to 52 weeks of age, child’s
sex, and original trial, whereas each unit increase in WLZ from
6 to 52 weeks of age was associated with an increased risk of
2.45 (95% CI 1.40-4.30) in the same model. Change in LAZ
from 6 to 52 weeks of age was also associated with an in-
creased risk of overweight in multivariate models. In multi-
variate models for obesity in midchildhood, baseline WAZ and
change in all 3 anthropometric indicators from 6 to 52 weeks
of age were associated significantly with an increased risk of
Table I. Characteristics of the 113 children who partici-
pated in midchildhood (4-9 years of age) assessments
Maternal characteristics
Age (y) 28.1 ± 5.0*
Height (cm) 157.2 ± 6.0
HIV infected, n (%) 47 (41.6)
Prior pregnancies, n (%)
0 31 (27.9)
1-4 74 (66.7)
≥5 6 (5.4)
Years of formal education 7.8 ± 2.7
Employment, n (%)
Housewife without income 61 (55.0)
Housewife with income 39 (35.1)
Other 11 (9.9)
Household characteristics
Household possessions†, n (%)
0 31 (27.9)
1-2 31 (27.9)
≥3 49 (44.1)
Child characteristics at baseline (5-7 wk)
Age at randomization (wk) 5.8 ± 0.3
Male sex, n (%) 51 (45.1)
Birthweight (kg) 3.16 ± 0.46
Gestational age at birth (wk) 40.0 ± 2.3
LAZ −0.18 ± 1.03
WAZ −0.27 ± 0.88
WLZ −0.12 ± 1.10
Flagellin IgG (adjusted optical density)‡ 0.43 ± 0.18
Flagellin IgA (adjusted optical density)‡ 0.30 ± 0.23
LPS IgG (adjusted optical density)‡ 0.72 ± 0.38
LPS IgA (adjusted optical density)‡ 0.41 ± 0.31
Child characteristics during 12-month follow-up in original
trials
Change in LAZ from baseline to 12 months −0.52 ± 1.08
Change in WAZ from baseline to 12 months −0.35 ± 1.06
Change in WLZ from baseline to 12 months −0.49 ± 1.52
Child characteristics at follow-up in midchildhood (4-9 y)
Age (y) 6.8 ± 1.6
HAZ −0.47 ± 1.1
WAZ −0.54 ± 1.0
BMIZ −0.40 ± 1.0
Stunting (HAZ <−2) 5 (4.4%)
Overweight (BMIZ >1) 9 (8.0%)
Obesity (BMIZ >2) 4 (3.5%)
Thinness (BMIZ <−2) 6 (5.3%)
Systolic blood pressure (mm Hg) 91.8 ± 9.9
Diastolic blood pressure (mm Hg) 54.1 ± 6.5
Mean arterial blood pressure (mm Hg) 64.8 ± 7.7
*Mean ± SD for all continuous variables; number and frequency (%) for all categorical variables.
†From a list that includes sofa, television, refrigerator and fan.
‡Only available in children in trial 2 (n = 66).
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obesity. In multivariate models for stunting in midchildhood,
baseline LAZ and change in LAZ from 6 to 52 weeks of age
were associated independently and negatively with risk of stunt-
ing (aRR 0.23 [95% CI 0.08-0.68; P = .008] and 0.31 [95% CI
0.13-0.77; P = .01], respectively). Change in WAZ and WLZ
from 6 to 52 weeks of age were also associated marginally and
significantly with a decreased risk of stunting in midchildhood.
Discussion
In this longitudinal study of 113 Tanzanian children, we
found that LAZ at age 6 weeks of age and change in LAZ in
the first year of life were both independent, positive
predictors of HAZ and independent negative predictors of
stunting in midchildhood. We also found that the 6-week
WAZ and WLZ, as well as changes in WAZ and WAZ in
the first year of life, were associated independently and
positively with BMIZ in midchildhood, and associated nega-
tively with risk of overweight and obesity. Although linear
growth in infancy was also associated with BMIZ, over-
weight, and obesity, this relationship was less robust than
that with weight-related variables; similarly, weight-related
indicators in infancy were less strongly correlated with height
variables in midchildhood. BMIZ in midchildhood was
associated in turn significantly and positively with systolic
Table II. Linear regression models for HAZ, BMIZ, andWAZ in midchildhood (4-9 years of age)
HAZ BMIZ WAZ
Univariate
models
Multivariate
models*
Univariate
models
Multivariate
models*
Univariate
models
Multivariate
models*
Baseline (6-week) measurements
LAZ†
Beta 0.33 0.47 0.04 0.16 0.25 0.42
95% CI 0.14 to 0.53 0.25 to 0.68 0.14 to 0.23 0.06 to 0.39 0.06 to 0.43 0.22 to 0.62
P value .001 <.001 .65 .15 .009 <.001
WAZ†
Beta 0.06 0.12 0.35 0.53 0.28 0.46
95% CI 0.19 to 0.30 0.13 to 0.37 0.14 to 0.56 0.30 to 0.76 0.06 to 0.50 0.24 to 0.67
P value .65 .33 .002 <.001 .01 <.001
WLZ†
Beta −0.34 −0.05 0.28 0.64 −0.02 0.43
95% CI 0.52 to −0.16 0.29 to 0.19 0.11 to 0.45 0.42 to 0.87 −0.20 to 0.16 0.21 to 0.65
P value <.001 .11 .001 <.001 .82 <.001
Flagellin IgG (adjusted optical density)‡
Beta −1.32 −1.36 0.36 0.46 −0.57 −0.52
95% CI −3.12 to 0.48 −3.11 to 0.38 −1.15 to 1.87 −1.10 to 2.02 −2.15 to 1.00 −2.09 to 1.04
P value .15 .12 .64 .56 .47 .50
Flagellin IgA (adjusted optical density)‡
Beta −0.02 −0.82 0.24 −0.15 0.19 −0.58
95% CI −1.44 to 1.40 −2.26 to 0.62 −0.93 to 1.42 −1.42 to 1.13 −1.04 to 1.41 −1.86 to 0.69
P value .98 .26 .68 .82 .76 .36
LPS IgG (adjusted optical density)‡
Beta 0.01 −0.44 −0.11 −0.19 −0.08 −0.40
95% CI −0.84 to 0.86 −1.28 to 0.41 −0.81 to 0.60 −0.94 to 0.55 −0.81 to 0.66 −1.14 to 0.34
P value .99 .31 .77 .60 .84 .28
LPS IgA (adjusted optical density)‡
Beta −0.61 −0.93 −0.06 −0.08 −0.41 −0.61
95% CI −1.62 to 0.41 −1.91 to 0.05 −0.91 to 0.79 −0.97 to 0.80 −1.29 to 0.47 −1.48 to 0.27
P value .24 .06 .90 .86 .35 .17
Change in anthropometry from 6 to 52 weeks
LAZ†
Beta 0.19 0.40 0.13 0.19 0.21 0.40
95% CI −0.01 to 0.38 0.20 to 0.61 −0.05 to 0.30 −0.02 to 0.40 0.03 to 0.39 0.21 to 0.59
P value .06 <.001 .16 .08 .02 <.001
WAZ†
Beta 0.28 0.35 0.21 0.32 0.33 0.45
95% CI 0.09 to 0.48 0.14 to 0.56 0.03 to 0.39 0.13 to 0.51 0.16 to 0.51 0.27 to 0.63
P value .004 .001 .02 <.001 <.001 <.001
WLZ†
Beta 0.33 0.29 0.07 0.38 0.27 0.45
95% CI 0.21 to 0.46 0.11 to 0.47 −0.06 to 0.20 0.21 to 0.54 0.15 to 0.38 0.29 to 0.62
P value <.001 .002 .28 <.001 <.001 <.001
*Multivariate models for HAZ, BMIZ, and WAZ in mid-childhood adjust for which trial the child originally participated in, treatment arm, maternal height (cm), maternal education (0, 1-7 or ≥8
years), and child's sex and age at follow-up. Multivariate models for BMIZ adjust for which trial the child originally participated in, treatment arm, maternal height (cm), maternal education (0, 1-7
or ≥8 years), and child's sex and age at follow-up. Multivariate models for WAZ adjust for which trial the child originally participated in, treatment arm, maternal height (cm), maternal education
(categories), and child's sex and age at follow-up.
†Multivariate models with anthropometric indicators as independent variables also include the corresponding anthropometric indicator at 6 weeks or change from 6 to 52 weeks of age, for example,
the model reporting the beta parameter for LAZ at 6 weeks adjusts for change in LAZ from 6 to 52 weeks of age, and vice versa.
‡n = 66 (children from second trial only).
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blood pressure, and serum anti-flagellin IgA in early
infancy was also a significant predictor of midchildhood
blood pressure.
Cohort studies in high-income countries have also found
that birthweight and weight gain in early life are positively cor-
related with BMI, overweight, and obesity later in life26,27;
however, our study is one of few to longitudinally follow-up
with infants from a low-income country over many years,28-32
particularly in sub-Saharan Africa.28 Our findings show that
in the resource-limited environment of Dar es Salaam, where
poor sanitation, high burdens of infectious disease, and sub-
optimal infant feeding practices contribute to high levels of
undernutrition in infancy,18-21 weight gain in early life
continues to track throughout childhood and ultimately
Table III. Linear regression models for systolic and diastolic blood pressure in midchildhood (4-9 years of age)
Systolic blood pressure Diastolic blood pressure
Univariate models Multivariate models* Univariate models Multivariate models*
Baseline (6-week) measurements
LAZ†
Beta 0.24 0.44 0.43 0.60
95% CI −1.57 to 2.05 −1.73 to 2.61 −0.75 to 1.62 −0.84 to 2.05
P value .79 .69 .47 .41
WAZ†
Beta 0.64 1.52 0.50 0.94
95% CI −1.50 to 2.79 −0.87 to 3.91 −0.90 to 1.89 −0.65 to 2.52
P value .55 .21 .48 .24
WLZ†
Beta 0.26 2.04 −0.07 0.85
95% CI −1.46 to 1.97 −0.44 to 4.52 −1.19 to 1.04 −0.80 to 2.50
P value .77 .11 .90 .31
Flagellin IgG (adjusted optical density)‡
Beta −0.97 4.58 3.60 7.36
95% CI −15.23 to 13.30 −12.11 to 21.27 −6.17 to 13.36 −4.30 to 19.01
P value .89 .58 .46 .21
Flagellin IgA (adjusted optical density)‡
Beta 17.67 17.81 12.08 13.95
95% CI 7.51 to 27.82 6.50 to 29.1 5.10 to 19.07 6.14 to 21.76
P value <.001 .003 .001 .001
LPS IgG (adjusted optical density)‡
Beta −2.23 −0.58 1.19 2.29
95% CI −8.84 to 4.38 −8.19 to 7.02 −3.36 to 5.74 −3.05 to 7.63
P value .50 .88 .60 .39
LPS IgA (adjusted optical density)‡
Beta −2.21 −1.71 −1.34 −1.39
95% CI −10.19 to 5.78 −10.67 to 7.25 −6.83 to 4.15 −7.72 to 4.94
P value .58 .70 .63 .66
Change in anthropometry from 6 to 52 weeks
LAZ†
Beta 0.58 0.80 −0.04 0.40
95% CI −1.15 to 2.31 −1.41 to 3.01 −1.18 to 1.10 −01.07 to 1.87
P value .50 .47 .95 .59
WAZ†
Beta 0.62 1.10 0.17 0.55
95% CI −1.16 to 2.39 −0.92 to 3.13 −0.99 to 1.33 −0.79 to 1.89
P value .49 .28 .78 .24
WLZ†
Beta 0.39 1.25 0.28 0.70
95% CI −0.97 to 1.76 −0.48 to 2.97 −0.52 to 1.09 −0.45 to 1.85
P value .57 .16 .49 .23
Anthropometry in midchildhood (4-9 years)
HAZ
Beta −0.21 −0.06 −0.51 −0.39
95% CI −1.86 to 1.44 −1.84 to 1.71 −1.59 to 0.58 −1.57 to 0.79
P value .80 .94 .36 .51
BMIZ
Beta 1.54 2.21 0.42 0.85
95% CI −0.26 to 3.35 0.40 to 4.02 −0.78 to 1.62 −0.39 to 2.08
P value .09 .02 .49 .18
*Multivariate models for systolic and diastolic blood pressure control for which trial the child participated in, treatment arm, child's sex, gestational age at birth, and age at mid-childhood follow-
up. Multivariate models diastolic blood pressure adjust for which trial the child originally participated in, whether the child was randomized to multivitamin supplementation, maternal height (cm),
child's gestational age at birth, and child's age at follow-up visit.
†Multivariate models with anthropometric indicators as predictors also include the corresponding anthropometric indicator at 6 weeks of age or change from 6 to 52 weeks of age, for example,
the model reporting the beta parameter for LAZ at 6 weeks adjusts for change in LAZ from 6 to 52 weeks of age, and vice versa.
‡n = 66 (children from second trial only).
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correlates with BMIZ and risk of overweight and obesity in
midchildhood.
Stunting in early life increases the risk of impaired cogni-
tive development, adult short stature, lower earning poten-
tial, and birth complications in women.3 We found that LAZ
at 6 weeks of age and change in LAZ from 6 to 52 weeks of
age were associated independently with height in midchildhood,
and that they were also correlated independently and in-
versely with stunting in midchildhood. Our findings thus em-
phasize the importance of nutritional status in both the
perinatal and infant periods to improve long-term nutrition
and health outcomes in children. Other studies have also found
that early life linear growth predicts attained height later in
childhood or adulthood29-35; however, less clear in the exist-
ing literature is the relationship between early life linear growth
and later BMI. A recent study pooling data from 5 cohorts in
low-income and middle-income countries found that, al-
though change in height in the first 2 years of life was asso-
ciated with a minor increase in risk of being overweight in
adulthood, increases in weight accounting for height in the first
2 years of life was a much stronger predictor of overweight in
adulthood.28 Our findings support the hypothesis that early
life gains in weight, particularly weight relative to height, has
negative consequences for increasing BMI and risk of over-
weight and obesity. We also found that linear growth in infancy
was associated with an increased risk of overweight and obesity
in midchildhood, though this association was less robust than
that of weight-related indicators and midchildhood BMIZ, over-
weight, and obesity. Further research on how interventions can
promote healthy linear growth without resulting in excess
weight gain in early infancy will be essential in addressing the
global dual burden of disease.
This study identified a strong relationship between flagellin
antibodies in early infancy and blood pressure in midchildhood.
The relationship between morbidity, particularly diarrheal
disease in infancy and malnutrition has been well-
documented1,36; however, researchers have only recently begun
to explore the important role of EED in malnutrition, high-
lighting that EED may lead to both micronutrient and mac-
ronutrient malabsorption.37-39 Currently, diagnosing EED
remains challenging. Small bowel biopsies have been consid-
ered the gold standard for the assessment of the mucosal struc-
ture; however, given the invasive and expensive nature of these
procedures, research is underway to determine biomarkers that
may be more appropriate for widespread use in community-
based studies.40,41 The bacterial protein flagellin mediates bac-
teria motility and is present in the gut lumen, even in a healthy
state; however, flagellin has very limited access to cross the epi-
thelium and reach the mucosal immune system. However, a
decrease in gut barrier function or an increase in levels of bac-
teria that produce flagellin might activate the adaptive immune
responses to these molecules, resulting in the generation of anti-
flagellin and anti-LPS antibodies, as has been shown to occur
in patients with short bowel syndrome42 and Crohn’s disease.43
Our group has previously shown that anti-flagellin IgA and
IgG concentrations increased over the first year of life in Tan-
zanian infants, that the concentrations in Tanzanian infants
were much higher than in healthy controls in Boston, and that
elevated anti-flagellin IgA and IgG concentrations were asso-
ciated with an increased risk of underweight in infancy.17 Our
current study also highlights that, in addition to its role in
malnutrition in infancy, EED, as measured by antibodies to bac-
terial components, may also play an important role in long-
term chronic disease risk,16 particularly when one considers
the research documenting the likelihood of blood pressure
tracking from childhood through adulthood.44 Of note, in our
sensitivity analyses, we added infant anthropometry to the mul-
tivariate models linking 6-week flagellin IgA and midchildhood
Figure. Flagellin IgA at 6 weeks and systolic and diastolic blood pressure in midchildhood (4-9 years of age).
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systolic and diastolic blood pressure, and found that this did
not reduce substantially the magnitude of the relationship
between flagellin IgA in infancy and midchildhood blood pres-
sure. Our findings, thus, support the hypothesis that EED in
infancy may affect long-term cardiometabolic outcomes
through pathways external to growth, such systemic inflam-
mation and epigenetic changes in immune function.16
Our study has several limitations. We do not have measure-
ments in children between infancy and the midchildhood
follow-up, and we only have biomarkers of EED at 6 weeks and
6 months of age, so we are limited in our ability to compare
critical periods of growth or to evaluate the potential impact
of EED on growth at other ages. It is also worth noting that
we only measured a limited set of cardiometabolic risk factors
that did not include insulin sensitivity or other vascular out-
comes, such as vascular reactivity. Our follow-up study sample
may also suffer from selection bias. In particular, the least well-
off children, that is, those who became ill, died, or moved since
the trial ended, are likely to be excluded from our follow-up
sample. However, given that developmental programming is
strongest when environmental insults are most severe, if our
study had included less healthy children (who likely would have
experienced greater growth faltering and EED in infancy), we
would have expected to see even stronger associations between
infant and midchildhood health indicators. By contrast, our
study is also limited by the low prevalence of overweight,
obesity, and stunting in this peri-urban African setting and,
thus, the limited power for analyses of binary outcomes. Our
estimates of overweight and obesity in this sample were,
however, comparable with other studies in Tanzanian
children.45,46 Although overweight and obesity are relatively rare
in Tanzanian children, a recent study found that 24.1% and
19.2% of adults in Kinondoni, 1 of 3 municipalities in Dar es
Salaam, are overweight and obese, respectively.47 We showed
that weight gain in early life tracks into midchildhood, and evi-
dence from other contexts indicates that weight gain in
midchildhood tracks into adulthood.48 As sub-Saharan Africa
continues to undergo the nutrition transition, it will be in-
creasingly important to monitor weight gain in infancy and
as children age.
Our study, and others, longitudinally tracked pediatric growth
from infancy into midchildhood in a sub-Saharan African
context.49,50 Given the rapid pace of the nutrition transition
in sub-Saharan Africa and the dual burden of preventing both
pediatric undernutrition but also chronic disease later in life,1
our study helps to elucidate the relationship between stan-
dard growth indicators in early infancy and health outcomes
in later life, as well as the possible role of EED in child health.
As the global health community continues to invest in the
healthy growth and development of children in sub-Saharan
Africa, an expanded emphasis beyond short-term outcomes
such a survival and treatment of malnutrition and infectious
disease will be essential to promote long-term health and
prevent obesity and cardiometabolic diseases. ■
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Table IV. Relative risks of overweight, obesity, and stunting in midchildhood (4-9 years)
Overweight (BMIZ > 1;
N = 113, overweight n = 9)
Obesity (BMIZ > 2;
N = 113, obese n = 4)
Stunting (HAZ < −2;
N = 113, stunted n = 6)
Univariate
models
Multivariate
models*
Univariate
models
Multivariate
models*
Univariate
models
Multivariate
models*,†
Baseline (6-week) measurements
LAZ
Risk ratio 1.24 1.94 1.16 2.46 0.25 0.23
95% CI 0.69-2.22 0.96-3.93 0.46-2.90 0.74-8.20 0.11-0.56 0.08-0.68
P value .48 .07 .76 .14 <.001 .008
WAZ
Risk ratio 1.46 2.16 1.25 3.33 0.54 0.26
95% CI 0.70-3.01 1.15-4.05 0.41-3.85 1.41-7.87 0.26-1.12 0.04-1.61
P value .31 .02 .69 .006 .10 .15
WLZ
Risk ratio 1.10 2.47 1.03 3.85 2.38 0.48
95% CI 0.63-1.92 1.04-5.90 0.43-2.45 0.74-20.17 0.98-5.78 0.11-2.04
P value .74 .04 .95 .11 .06 .32
Change in anthropometry from 6 to 52 weeks
LAZ
Risk ratio 1.60 2.37 2.03 4.03 0.68 0.31
95% CI 0.99-2.58 1.21-4.63 1.04-3.96 1.32-12.33 0.34-1.36 0.13-0.77
P value .053 .01 .04 .01 .28 .01
WAZ
Risk ratio 1.67 3.13 2.24 7.54 0.32 0.22
95% CI 1.18-2.36 1.50-6.52 1.40-3.58 3.12-18.22 0.12-0.86 0.04-1.13
P value .004 .002 <.001 <.001 .02 .07
WLZ
Risk ratio 1.52 2.45 2.10 4.66 0.40 0.27
95% CI 1.04-2.23 1.40-4.30 1.19-3.70 1.59-13.67 0.23-0.70 0.06-1.20
P value .03 .002 .01 .005 .02 .08
*Multivariate models adjust for which trial the child originally participated in and child's sex as well as the corresponding anthropometric indicator at 6 weeks or change from 6 to 52 weeks of
age, for example, the model reporting the beta parameter for LAZ at 6 weeks of age adjusts for change in LAZ from 6 to 52 weeks of age, and vice versa.
†Multivariate model for stunting in midchildhood also adjusts for maternal height (cm).
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